Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ziheng Peng, Duo Xu, Yong Li, Xiaowei Liu, Fujun Li & Yu Peng. (2023) A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease. Annals of Medicine 55:1.
Read now
Read now
Yanyan Wang, Chengyong Li, Weiyi Wang, Jiajia Wang, Jinhui Li, Shuangjie Qian, Chao Cai & Yuntao Liu. (2022) Serum Albumin to Globulin Ratio is Associated with the Presence and Severity of Inflammatory Bowel Disease. Journal of Inflammation Research 15, pages 1907-1920.
Read now
Read now
Consuelo Sauceda, Charlie Bayne, Khadijeh Sudqi, Antonio Gonzalez, Parambir S. Dulai, Rob Knight, David J. Gonzalez & Carlos G. Gonzalez. (2022) Stool multi-omics for the study of host–microbe interactions in inflammatory bowel disease. Gut Microbes 14:1.
Read now
Read now
R. Gacesa, A. Vich Vila, V. Collij, Z. Mujagic, A. Kurilshikov, M.D. Voskuil, E.A.M. Festen, C. Wijmenga, D.M.A.E. Jonkers, G. Dijkstra, J. Fu, A. Zhernakova, F. Imhann & R.K. Weersma. (2021) A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease. Gut Microbes 13:1.
Read now
Read now
Ferdinando D’Amico, Gionata Fiorino, Federica Furfaro, Mariangela Allocca, Giulia Roda, Laura Loy, Alessandra Zilli, Virginia Solitano, Laurent Peyrin-Biroulet & Silvio Danese. (2020) Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Review of Gastroenterology & Hepatology 14:9, pages 765-773.
Read now
Read now
Christopher Ma, Robert Battat, Claire E. Parker, Reena Khanna, Vipul Jairath & Brian Gordon Feagan. (2019) Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?. Expert Review of Gastroenterology & Hepatology 13:4, pages 319-330.
Read now
Read now
Takayuki Yamamoto & Takahiro Shimoyama. (2017) Monitoring and detection of disease recurrence after resection for Crohn’s disease: the role of non-invasive fecal biomarkers. Expert Review of Gastroenterology & Hepatology 11:10, pages 899-909.
Read now
Read now
Articles from other publishers (75)
Peter Rimmer & Tariq Iqbal. (2023) Prognostic modelling in IBD. Best Practice & Research Clinical Gastroenterology, pages 101877.
Crossref
Crossref
Junrong Li, Mingyang Xu, Wei Qian, Fangmei Ling, Yidong Chen, Shuang Li, Yiyu Cheng & Liangru Zhu. (2023) Clinical value of fecal calprotectin for evaluating disease activity in patients with Crohn’s disease. Frontiers in Physiology 14.
Crossref
Crossref
T. Kucharzik, B. Verstockt & C. Maaser. (2023) Monitoring of patients with active inflammatory bowel disease. Frontiers in Gastroenterology 2.
Crossref
Crossref
Nurulamin M Noor & James C Lee. (2023) The Endoscopic Healing Index in Crohn’s Disease: A Serum Proteomic Biomarker for Monitoring Disease Activity. Inflammatory Bowel Diseases 29:4, pages 669-671.
Crossref
Crossref
Ariela K Holmer, Brigid S Boland, Siddharth Singh, Jennifer Neill, Helen Le, Ara Miralles, Angelina E Collins, William J Sandborn & Parambir S Dulai. (2023) A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn’s Disease. Inflammatory Bowel Diseases 29:4, pages 555-562.
Crossref
Crossref
Sem Geertsema, Antonius T Otten, Dianne G Bouwknegt, Marijn C Visschedijk & Arno R Bourgonje. (2023) Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 29:3, pages e10-e11.
Crossref
Crossref
Patricia Latorre Añó, Jorge Torrente Sánchez, Amparo Almudena Pérez Ibañez, Jose María Tenias Burillo, Nadia Paloma Moreno Sánchez, Antonio López-Serrano, Eduardo Moreno Osset, Julián Murado Pardo & José María Paredes. (2023) Fecal immunochemical test for haemoglobin versus fecal calprotectin to monitoring endoscopic activity in inflammatory bowel disease. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Aisha Augustin, Adrien Le Guennec, Chianna Umamahesan, Aidan Kendler‐Rhodes, Rosalind M. Tucker, Elena Chekmeneva, Panteleimon Takis, Matthew Lewis, Karthik Balasubramanian, Neville DeSouza, Benjamin H Mullish, David Taylor, Suzanne Ryan, Kevin Whelan, Yun Ma, Mohammad A. A. Ibrahim, Ingvar Bjarnason, Bu’ Hussain Hayee, André Charlett, Sylvia M. Dobbs, R. John Dobbs & Clive Weller. (2023) Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome. Clinical and Translational Medicine 13:1.
Crossref
Crossref
F de Voogd, S Bots, K Gecse, O H Gilja, G D’Haens & K Nylund. (2022) Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFα Treatment in Crohn’s Disease. Journal of Crohn's and Colitis 16:10, pages 1598-1608.
Crossref
Crossref
Valeria Rios Rodriguez, Elena Sonnenberg, Fabian Proft, Mikhail Protopopov, Michael Schumann, Lea I. Kredel, Judith Rademacher, Murat Torgutalp, Hildrun Haibel, Maryna Verba, Britta Siegmund & Denis Poddubnyy. (2022) Presence of spondyloarthritis associated to higher disease activity and HLA-B27 positivity in patients with early Crohn's disease: Clinical and MRI results from a prospective inception cohort. Joint Bone Spine 89:5, pages 105367.
Crossref
Crossref
Carlos G. Gonzalez, Robert H. Mills, Qiyun Zhu, Consuelo Sauceda, Rob Knight, Parambir S. Dulai & David J. Gonzalez. (2022) Location-specific signatures of Crohn’s disease at a multi-omics scale. Microbiome 10:1.
Crossref
Crossref
Jennifer Hellmann, Allison Ta, Nicholas J Ollberding, Ramona Bezold, Kathleen Lake, Kimberly Jackson, Kelsie Dirksing, Erin Bonkowski, David B Haslam & Lee A Denson. (2022) Patient-Reported Outcomes Correlate With Microbial Community Composition Independent of Mucosal Inflammation in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases.
Crossref
Crossref
José María Paredes, Tomás Ripollés, Ángela Algarra, Rafael Diaz, Nadia Moreno, Patricia Latorre, María Jesús Martínez, Pilar Llopis, Antonio López & Eduardo Moreno-Osset. (2022) Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests. Intestinal Research 20:3, pages 361-369.
Crossref
Crossref
Yoo Min Lee, Sujin Choi, Byung-Ho Choe, Hyo-Jeong Jang, Seung Kim, Hong Koh, Eun Sil Kim, Mi Jin Kim, Yon Ho Choe & Ben Kang. (2022) Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents. Gut and Liver 16:1, pages 62-70.
Crossref
Crossref
Sun-Ho Lee, Williams Turpin, Osvaldo Espin-Garcia, Juan Antonio Raygoza Garay, Michelle I. Smith, Haim Leibovitzh, Ashleigh Goethel, Dan Turner, David Mack, Colette Deslandres, Maria Cino, Guy Aumais, Remo Panaccione, Kevan Jacobson, Alain Bitton, A. Hillary Steinhart, Hien Q. Huynh, Fred Princen, Paul Moayyedi, Anne M. Griffiths, Mark S. Silverberg, Andrew D. Paterson, Wei Xu & Kenneth Croitoru. (2021) Anti-Microbial Antibody Response is Associated With Future Onset of Crohn’s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology 161:5, pages 1540-1551.
Crossref
Crossref
Nicolas Pierre, Catherine Salée, Sophie Vieujean, Emeline Bequet, Angela‐Maria Merli, Britta Siegmund, Marie‑Alice Meuwis & Edouard Louis. (2021) Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Alimentary Pharmacology & Therapeutics 54:6, pages 779-791.
Crossref
Crossref
Jéssica A. Barbosa, Lucas A. Rodrigues, Daniel A. Columbus, Juan C. P. Aguirre, John C. S. Harding, Vinícius S. Cantarelli & Matheus de O. Costa. (2021) Experimental infectious challenge in pigs leads to elevated fecal calprotectin levels following colitis, but not enteritis. Porcine Health Management 7:1.
Crossref
Crossref
Margaret Walshe, Krzysztof Borowski, Robert Battat, David Hudesman, Douglas C Wolf, Lauren Okada, Anjali Jain & Mark S Silverberg. (2021) Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index. Crohn's & Colitis 360 3:3.
Crossref
Crossref
Anthony Buisson, Wing Yan Mak, Michael J AndersenJrJr, Donald Lei, Joel Pekow, Russell D Cohen, Stacy A Kahn, Bruno Pereira & David T Rubin. (2021) Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn’s Disease Regardless of Disease Location. Inflammatory Bowel Diseases 27:7, pages 1008-1016.
Crossref
Crossref
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, Constanza Bay & Patricio Ibañez. (2021) Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología 44:4, pages 312-319.
Crossref
Crossref
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, Constanza Bay & Patricio Ibañez. (2021) Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología (English Edition) 44:4, pages 312-319.
Crossref
Crossref
Emiko Mizoguchi, Renuka Subramaniam, Toshiyuki Okada & Atsushi Mizoguchi. (2021) A Review of Selected IBD Biomarkers: From Animal Models to Bedside. Diagnostics 11:2, pages 207.
Crossref
Crossref
Ferdinando D’Amico, Stéphane Nancey, Silvio Danese & Laurent Peyrin-Biroulet. (2021) A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. Journal of Crohn's and Colitis 15:1, pages 152-161.
Crossref
Crossref
Rocio Cabra-Rodríguez, Miguel Ángel Castaño López, Ana María Serrano Mira, Antonio León-Justel, Ignacio Vázquez Rico, Juan María Vázquez Morón & Francisco Navarro Roldán. (2021) Comparative study between different methods for the determination of fecal calprotectin. Revista de Medicina de Laboratorio.
Crossref
Crossref
Gabriele Dragoni, Tommaso Innocenti & Andrea Galli. (2021) Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?. Digestive Diseases 39:3, pages 190-203.
Crossref
Crossref
Jurij Hanžel, Jurij Zdovc, Tina Kurent, Nejc Sever, Katarina Javornik, Katja Tuta, Matic Koželj, Nataša Smrekar, Gregor Novak, Borut Štabuc, Erwin Dreesen, Debby Thomas, Tomaž Vovk, Iztok Grabnar & David Drobne. (2021) Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission. Clinical Gastroenterology and Hepatology 19:1, pages 111-118.e10.
Crossref
Crossref
Giulia D’Arcangelo & Marina Aloi. (2020) Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say?. Pediatric Drugs 22:5, pages 463-472.
Crossref
Crossref
Eran Zittan, Ian M. Gralnek & Marc S. Berns. (2020) The New Proactive Approach and Precision Medicine in Crohn’s Disease. Biomedicines 8:7, pages 193.
Crossref
Crossref
Małgorzata Krzystek-Korpacka, Radosław Kempiński, Mariusz Bromke & Katarzyna Neubauer. (2020) Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics 10:6, pages 367.
Crossref
Crossref
Parambir S. Dulai & Vipul Jairath. (2020) How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?. Clinical Gastroenterology and Hepatology 18:6, pages 1300-1308.
Crossref
Crossref
Andrew Ming-Liang Ong. (2020) Utility of gastrointestinal ultrasound in functional gastrointestinal disorders: A narrative review. World Journal of Meta-Analysis 8:2, pages 109-118.
Crossref
Crossref
Thomas Chateau & Laurent Peyrin‐Biroulet. (2020) Evolving therapeutic goals in Crohn's disease management. United European Gastroenterology Journal 8:2, pages 133-139.
Crossref
Crossref
Filippo Vernia, Mirko Di Ruscio, Gianpiero Stefanelli, Angelo Viscido, Giuseppe Frieri & Giovanni Latella. (2019) Is fecal calprotectin an accurate marker in the management of Crohn's disease?. Journal of Gastroenterology and Hepatology 35:3, pages 390-400.
Crossref
Crossref
Laura Francesca Pisani, Manuela Moriggi, Cecilia Gelfi, Maurizio Vecchi & Luca Pastorelli. (2020) Proteomic insights on the metabolism in inflammatory bowel disease. World Journal of Gastroenterology 26:7, pages 696-705.
Crossref
Crossref
Geert D’Haens, Orlaith Kelly, Robert Battat, Mark S. Silverberg, David Laharie, Edouard Louis, Edoardo Savarino, Giorgia Bodini, Andres Yarur, Brigid S. Boland, Waqqas Afif, Xiao-jun Li, Michael Hale, Jessica Ho, Venkateswarlu Kondragunta, Benjamin Huang, Crystal Kuy, Lauren Okada, Kelly D. Hester, Kurtis R. Bray, Larry Mimms, Anjali Jain, Siddharth Singh, Angelina Collins, Mark A. Valasek, William J. Sandborn, Severine Vermeire & Parambir S. Dulai. (2020) Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn’s Disease Based on Serum Levels of Proteins. Gastroenterology 158:3, pages 515-526.e10.
Crossref
Crossref
Bingjie Xiang, Ziyuan Dong & Cong Dai. (2020) The diagnostic and predictive value of Fecal calprotectin and capsule endoscopy for small-bowel Crohn�s disease: A systematic review and meta-analysis. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Cong Dai, Min Jiang & Ming-Jun Sun. (2020) Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease. Clinical Gastroenterology and Hepatology 18:1, pages 262.
Crossref
Crossref
Nurulamin M Noor, Bram Verstockt, Miles Parkes & James C Lee. (2020) Personalised medicine in Crohn's disease. The Lancet Gastroenterology & Hepatology 5:1, pages 80-92.
Crossref
Crossref
Parambir S. Dulai, Siddharth Singh, Niels Vande Casteele, Brigid S. Boland, Jesus Rivera-Nieves, Peter B. Ernst, Lars Eckmann, Kim E. Barrett, John T. Chang & William J. Sandborn. (2019) Should We Divide Crohn’s Disease Into Ileum-Dominant and Isolated Colonic Diseases?. Clinical Gastroenterology and Hepatology 17:13, pages 2634-2643.
Crossref
Crossref
Marjolein A Y Klaassen, Floris Imhann, Valerie Collij, Jingyuan Fu, Cisca Wijmenga, Alexandra Zhernakova, Gerard Dijkstra, Eleonora A M Festen, Ranko Gacesa, Arnau Vich Vila & Rinse K Weersma. (2019) Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn’s Disease Exacerbations. Journal of Crohn's and Colitis 13:11, pages 1439-1449.
Crossref
Crossref
Antonio Tursi, Giammarco Mocci, Roberto Faggiani, Leonardo Allegretta, Nicola Della Valle, Antonio de Medici, Giacomo Forti, Marilisa Franceschi, Antonio Ferronato, Sara Gallina, Giuseppina Grasso, Tiziana Larussa, Francesco Luzza, Roberto Lorenzetti, Antonio Penna, Stefano Rodino'Ladislava Sebkova, Angelo Lauria, Simona Piergallini, Giuseppe Pranzo, Stefano Scorza, Costantino Zampaletta, Marcello Picchio & Walter Elisei. (2019) Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. European Journal of Internal Medicine 66, pages 85-91.
Crossref
Crossref
Andrew S. DayShaun S.C. Ho & Steven T. Leach. (2019) Letter to the Editor Re: Serum Calprotectin in Adolescents With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 68:6, pages e109.
Crossref
Crossref
Toer W Stevens, Geert R D'Haens, Marjolijn Duijvestein, Willem A Bemelman, Christianne J Buskens & Krisztina B Gecse. (2019) Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas. United European Gastroenterology Journal 7:4, pages 496-506.
Crossref
Crossref
Ebby George Simon, Richard Wardle, Aye Aye Thi, Jeanette Eldridge, Sunil Samuel & Gordon William Moran. (2019) Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease?: a systematic review. Intestinal Research 17:2, pages 160-170.
Crossref
Crossref
Robert Venning Bryant, Christopher G Schultz, Soong Ooi, Charlotte Goess, Samuel Paul Costello, Andrew D Vincent, Scott Schoeman, Amanda Lim, Francis Dylan Bartholomeusz, Simon P L Travis & Jane Mary Andrews. (2019) Visceral Adipose Tissue Is Associated With Stricturing Crohn’s Disease Behavior, Fecal Calprotectin, and Quality of Life. Inflammatory Bowel Diseases 25:3, pages 592-600.
Crossref
Crossref
Christopher Ma, Robert Battat, Reena Khanna, Claire E. Parker, Brian G. Feagan & Vipul Jairath. (2019) What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. Best Practice & Research Clinical Gastroenterology 38-39, pages 101602.
Crossref
Crossref
Satwik Motaganahalli, Lauren Beswick, Danny Con & Daniel R. van Langenberg. (2019) Faecal calprotectin delivers on convenience, cost reduction and clinical decision‐making in inflammatory bowel disease: a real‐world cohort study. Internal Medicine Journal 49:1, pages 94-100.
Crossref
Crossref
Sara Monteiro, Mara Barbosa, Tiago Cúrdia Gonçalves, Pedro Boal Carvalho, Maria João Moreira, Bruno Rosa & José Cotter. (2018) Fecal Calprotectin as a Selection Tool for Small Bowel Capsule Endoscopy in Suspected Crohn’s Disease. Inflammatory Bowel Diseases 24:9, pages 2033-2038.
Crossref
Crossref
Kenji Watanabe, Takayuki Matsumoto, Tadakazu Hisamatsu, Hiroshi Nakase, Satoshi Motoya, Naoki Yoshimura, Tetsuya Ishida, Shingo Kato, Tomoo Nakagawa, Motohiro Esaki, Masakazu Nagahori, Toshiyuki Matsui, Yuji Naito, Takanori Kanai, Yasuo Suzuki, Masanori Nojima, Mamoru Watanabe, Toshifumi Hibi, Akira Andoh, Toshifumi Ashida, Katsuya Endo, Yutaka Endo, Motohiro Esaki, Hiroshi Fujita, Mikihiro Fujiya, Ken Haruma, Toshifumi Hibi, Sakiko Hiraoka, Ichiro Hirata, Tadakazu Hisamatsu, Yutaka Honda, Hideki Iijima, Bunei Iizuka, Kentaro Ikeya, Takuya Inoue, Syuji Inoue, Tetsuya Ishida, Yo Ishiguro, Shyunji Ishihara, Hiroaki Ito, Ryuichi Iwakiri, Takashi Kagaya, Takanori Kanai, Hiroshi Kashida, Shingo Kato, Jun Kato, Takehiko Katsurada, Fukunori Kinjyo, Kiyonori Kobayashi, Mayumi Kodama, Reiko Kunisaki, Koichi Kurahara, Takafumi Kurokami, Lee Kyouwon, Koichiro Matsuda, Kazuhiro Matsueda, Toshiyuki Matsui, Takayuki Matsumoto, Keiichi Mitsuyama, Yuji Mizokami, Satoshi Motoya, Yuji Naito, Tomoo Nakagawa, Shiro Nakamura, Hiroshi Nakase, Masanori Nojima, Masafumi Nomura, Atsuhiro Ogawa, Kazuichi Okazaki, Kazuaki Otsuka, Hirotake Sakuraba, Masayuki Saruta, Makoto Sasaki, Takayuki Shirai, Tomoaki Suga, Kazuhito Sugimura, Toshiro Sugiyama, Yasuo Suzuki, Fuminao Takeshima, Hiroyuki Tamaki, Shinji Tanaka, Satoshi Tanida, Keiichi Tominaga, Taku Tomizawa, Kenji Watababe, Mamoru Watanabe, Kenji Watanabe, Syojiro Yamamoto, Masaki Yamashita, Atsushi Yoshida & Naoki Yoshimura. (2018) Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 16:4, pages 542-549.e1.
Crossref
Crossref
Grazyna Piotrowicz, Agnieszka Klufczyńska, Jacek Kowerzanow, Piotr Banaszkiewicz,Grażyna Rydzewska. (2018) Crohn’s disease activity evaluation based on imaging studies and biomarkers. Gastroenterology & Hepatology: Open Access 9:2.
Crossref
Crossref
Cong Dai, Min Jiang & Ming-jun Sun. (2017) Fecal Calprotectin in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Digestive Diseases and Sciences 62:12, pages 3625-3626.
Crossref
Crossref
Daniël R. Hoekman, Judith Zeevenhooven, Geert R. D’Haens & Marc A. Benninga. (2017) The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission. European Journal of Gastroenterology & Hepatology 29:9, pages 1086-1090.
Crossref
Crossref
Takahiro Shimoyama, Takayuki Yamamoto, Satoru Umegae & Koichi Matsumoto. (2017) Faecal biomarkers for screening small bowel inflammation in patients with Crohn’s disease: a prospective study. Therapeutic Advances in Gastroenterology 10:8, pages 577-587.
Crossref
Crossref
Andrew S. Day & Mustafa Adamji. (2017) Commentary: Impact of Fecal Calprotectin Measurement on Decision-Making in Children with Inflammatory Bowel Disease. Frontiers in Pediatrics 5.
Crossref
Crossref
Alexandre Loktionov, Vivek Chhaya, Tatiana Bandaletova & Andrew Poullis. (2017) Inflammatory bowel disease detection and monitoring by measuring biomarkers in non-invasively collected colorectal mucus. Journal of Gastroenterology and Hepatology 32:5, pages 992-1002.
Crossref
Crossref
M. J. Lee, N. Heywood, P. M. Sagar, S. R. Brown & N. S. Fearnhead. (2017) Association of Coloproctology of Great Britain and Ireland consensus exercise on surgical management of fistulating perianal Crohn's disease. Colorectal Disease 19:5, pages 418-429.
Crossref
Crossref
Jose C. Gallego & Ana Echarri. (2017) Is there a role of magnetic resonance imaging in deciding to stop anti-tumor necrosis factor treatment in ileal Crohn's disease?. Clinical Imaging 43, pages 175-179.
Crossref
Crossref
M. G. Ward, P. A. Thwaites, L. Beswick, J. Hogg, G. Rosella, D. Van Langenberg, J. Reynolds, P. R. Gibson & M. P. Sparrow. (2017) Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Alimentary Pharmacology & Therapeutics 45:8, pages 1135-1145.
Crossref
Crossref
K. Diederen, D. R. Hoekman, A. Leek, V. M. Wolters, T. Z. Hummel, T. G. de Meij, B. G. P. Koot, M. M. Tabbers, M. A. Benninga & A. Kindermann. (2017) Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Alimentary Pharmacology & Therapeutics 45:7, pages 951-960.
Crossref
Crossref
Cong Dai, Ming-Jun Sun & Min Jiang. (2017) Level of Fecal Calprotectin and the Severity of Small Bowel Crohn?s Disease. Clinical Gastroenterology and Hepatology 15:2, pages 320-321.
Crossref
Crossref
Marcel Vetter, M. F. Neurath & Raja Atreya. (2017) Biomarker verbessern Versorgung des M. CrohnCrohn?s disease ? use of biomarkers in general practice. MMW - Fortschritte der Medizin 159:3, pages 63-68.
Crossref
Crossref
Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Korybalska, Natasza Czepulis, Joanna Luczak, Liliana Lykowska-Szuber, Iwona Krela-Kazmierczak, Krzysztof Linke & Janusz Witowski. (2017) Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies. World Journal of Gastroenterology 23:1, pages 135.
Crossref
Crossref
Cátia Arieira, Francisca Dias de Castro, Bruno Rosa, Maria João Moreira, João Firmino-Machado & José Cotter. (2017) Can we rely on inflammatory biomarkers for the diagnosis and monitoring Crohns disease activity?. Revista Española de Enfermedades Digestivas 109.
Crossref
Crossref
Hana Manceau, Valérie Chicha-Cattoir, Hervé Puy & Katell Peoc’h. (2017) Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clinical Chemistry and Laboratory Medicine (CCLM) 55:4.
Crossref
Crossref
Liran Domachevsky, Haim Leibovitzh, Irit Avni-Biron, Lev Lichtenstein, Natalia Goldberg, Meital Nidam, David Groshar, Hanna Bernstine & Ofer Ben-Bassat. (2017) Correlation of 18F-FDG PET/MRE Metrics with Inflammatory Biomarkers in Patients with Crohn’s Disease: A Pilot Study. Contrast Media & Molecular Imaging 2017, pages 1-9.
Crossref
Crossref
Tsunetaka Arai, Ken Takeuchi, Miyuki Miyamura, Rumiko Ishikawa, Akihiro Yamada, Masao Katsumata, Yoshinori Igarashi & Yasuo Suzuki. (2017) Level of Fecal Calprotectin Correlates With Severity of?Small?Bowel Crohn?s Disease, Measured by Balloon-assisted?Enteroscopy and Computed Tomography?Enterography. Clinical Gastroenterology and Hepatology 15:1, pages 56-62.
Crossref
Crossref
Alissa J. Walsh, Robert V. Bryant & Simon P. L. Travis. (2016) Current best practice for disease activity assessment in IBD. Nature Reviews Gastroenterology & Hepatology 13:10, pages 567-579.
Crossref
Crossref
Johannan F. Brandse, Roel J. Bennink, Susanne van Eeden, Mark L?wenberg, Gijs R. van den Brink & Geert R. D?Haens. (2016) Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis. Inflammatory Bowel Diseases 22:6, pages 1384-1390.
Crossref
Crossref
Jason Orlando Dimitri Musci, Jack Stephen Cornish & Jan Däbritz. (2016) Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. Journal of Gastroenterology 51:6, pages 531-547.
Crossref
Crossref
Kerri L. Novak, Deepti Jacob, Gilaad G. Kaplan, Emma Boyce, Subrata Ghosh, Irene Ma, Cathy Lu, Stephanie Wilson & Remo Panaccione. (2016) Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea. Canadian Journal of Gastroenterology and Hepatology 2016, pages 1-7.
Crossref
Crossref
F. Goutorbe, M. Goutte, R. Minet-Quinard, A-L. Boucher, B. Pereira, G. Bommelaer & A. Buisson. (2015) Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn’s Disease. Journal of Crohn's and Colitis 9:12, pages 1113-1119.
Crossref
Crossref
Juana Mosele, Alba Macià & Maria-José Motilva. (2015) Metabolic and Microbial Modulation of the Large Intestine Ecosystem by Non-Absorbed Diet Phenolic Compounds: A Review. Molecules 20:9, pages 17429-17468.
Crossref
Crossref
Takayuki Yamamoto & Takahiro Shimoyama. (2015) Can Fecal Biomarkers Detect Ileal Inflammation in Inflammatory Bowel Disease?. American Journal of Gastroenterology 110:9, pages 1370.
Crossref
Crossref
Wei-Chen Lin. (2015) Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World Journal of Gastroenterology 21:48, pages 13566.
Crossref
Crossref
Shannon Chang. (2015) Disease monitoring in inflammatory bowel disease. World Journal of Gastroenterology 21:40, pages 11246.
Crossref
Crossref